BACKGROUND: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer with poor disease outcome. The chemotherapeutic agent paclitaxel (PA) is commonly used as a second-line treatment in SCLC, but response rates are low. MATERIALS AND METHODS: 86M1 SCLC cells were treated in the presence or absence of paclitaxel and TRAIL or the combination for 24 hours. Western blot analysis was utilized to examine protein expression, cell surface protein expression and membrane integrity were elucidated by flow cytometry, and immunofluorescence microscopy was used to demonstrate translocation of proteins to the cell nucleus. RESULTS: Human 86M1 SCLC cells were found to be resistant to PA killing in vitro. This resistance is mediated by up-regulation of pro-survival protein BCL-xl. However, PA also increases surface expression of death receptors 4 and 5 (DR4 and DR5, respectively). The death receptors' ligand increased SCLC killing by PA through an apparent caspase-independent route involving activation/translocation of AIF. CONCLUSION: The addition of TRAIL to PA can potentiate apoptosis in a relatively PA-resistant SCLC line (specifically 86M1 cells). More importantly, we are the first to report an active method of resistance to paclitaxel in SCLC via BCL-xl up-regulation.
BACKGROUND:Small cell lung cancer (SCLC) is the most aggressive form of lung cancer with poor disease outcome. The chemotherapeutic agent paclitaxel (PA) is commonly used as a second-line treatment in SCLC, but response rates are low. MATERIALS AND METHODS: 86M1 SCLC cells were treated in the presence or absence of paclitaxel and TRAIL or the combination for 24 hours. Western blot analysis was utilized to examine protein expression, cell surface protein expression and membrane integrity were elucidated by flow cytometry, and immunofluorescence microscopy was used to demonstrate translocation of proteins to the cell nucleus. RESULTS:Human 86M1 SCLC cells were found to be resistant to PA killing in vitro. This resistance is mediated by up-regulation of pro-survival protein BCL-xl. However, PA also increases surface expression of death receptors 4 and 5 (DR4 and DR5, respectively). The death receptors' ligand increased SCLC killing by PA through an apparent caspase-independent route involving activation/translocation of AIF. CONCLUSION: The addition of TRAIL to PA can potentiate apoptosis in a relatively PA-resistant SCLC line (specifically 86M1 cells). More importantly, we are the first to report an active method of resistance to paclitaxel in SCLC via BCL-xl up-regulation.
Authors: Narayan Shivapurkar; Jyotsna Reddy; Hittu Matta; Ubaradka G Sathyanarayana; C X Huang; Shinichi Toyooka; John D Minna; Preet M Chaudhary; Adi F Gazdar Journal: Oncogene Date: 2002-12-05 Impact factor: 9.867
Authors: S Hopkins-Donaldson; A Ziegler; S Kurtz; C Bigosch; D Kandioler; C Ludwig; U Zangemeister-Wittke; R Stahel Journal: Cell Death Differ Date: 2003-03 Impact factor: 15.828
Authors: Isabelle Viard-Leveugle; Sylvie Veyrenc; Lars E French; Christian Brambilla; Elisabeth Brambilla Journal: J Pathol Date: 2003-10 Impact factor: 7.996
Authors: Matthew B Schabath; Anna R Giuliano; Zachary J Thompson; Ernest K Amankwah; Jhanelle E Gray; David A Fenstermacher; Kristen A Jonathan; Amer A Beg; Eric B Haura Journal: Carcinogenesis Date: 2013-07-09 Impact factor: 4.944
Authors: Susann Voigt; Stephan Philipp; Parvin Davarnia; Supandi Winoto-Morbach; Christian Röder; Christoph Arenz; Anna Trauzold; Dieter Kabelitz; Stefan Schütze; Holger Kalthoff; Dieter Adam Journal: BMC Cancer Date: 2014-02-07 Impact factor: 4.430
Authors: Seema-Maria Nathwani; Lisa M Greene; Stefania Butini; Giuseppe Campiani; D Clive Williams; Afshin Samali; Eva Szegezdi; Daniela M Zisterer Journal: Int J Oncol Date: 2016-05-12 Impact factor: 5.650